Merck, SpringWorks
These are the kinds of stocks long-term investors will often be interested in, since they must have excellent, resilient ...
Merck (MRK) stock is sinking 10% after the company provided weaker-than-expected 2025 guidance amid weak sales of Gardasil, its HPV vaccine. Additionally, the huge drug maker withdrew its long-term ...
The Committee for Medicinal Products for Human Use (CHMP) has recommended that Capvaxive be used to prevent invasive disease ...
For the recently completed fourth quarter, Merck booked an adjusted profit of $1.72 per share on $15.6 billion in revenue. Sales of top-selling cancer treatment Keytruda climbed 19% to $7.84 billion ...
Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania and New Jersey, isn’t too enthused about its prospects in 2025.
Rahway: Merck, known as MSD outside of the United States and Canada, has announced the initiation of waveLINE-010, a pivotal ...
Merck reported Q4 sales of $15.62 billion, up 7% YoY, exceeding the $15.49 billion estimate. Goldman Sachs raises Merck's price target to $135, citing growth potential. NOW OPEN: 200 Charter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback